Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety

TRIAL DESIGN: Open-label, randomised, controlled, pilot proof-of-concept clinical trial. METHODS: Participants: Antiretroviral naïve adult males with CD4 count ≥ 350 cells/mm(3). Interventions: Patients were randomised to receive thalidomide 200 mg QD for 3 weeks (Thalidomide group) or not (Control...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergara, Tânia R.C., Samer, Sadia, Santos-Oliveira, Joanna R., Giron, Leila B., Arif, Muhammad Shoaib, Silva-Freitas, Maria Luciana, Cherman, Lia A., Treitsman, Mauro S., Chebabo, Alberto, Sucupira, Maria Cecilia A., Da-Cruz, Alda M., Diaz, Ricardo Sobhie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605327/
https://www.ncbi.nlm.nih.gov/pubmed/28822719
http://dx.doi.org/10.1016/j.ebiom.2017.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605327/
https://www.ncbi.nlm.nih.gov/pubmed/28822719
http://dx.doi.org/10.1016/j.ebiom.2017.08.007

Ejemplares similares